Therapeutic effects of ethyl pyruvate on tumor growth and metastasis in a severe combined immunodeficiency mouse orthotopic implantation model

European Journal of Inflammation

Volumn 10, Issue 1, 2012, Pages 25-32

  Zhang, J ^a   Zhu, Jin Shui ^a   Zhou, Z ^a   Chen, W X ^a   Chen, N W ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Ethyl pyruvate; Gastric cancer; Growth; High mobility group box B1; Metastasis; Receptor for advanced glycation endproducts

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIINFLAMMATORY AGENT; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; PYRUVIC ACID DERIVATIVE; PYRUVIC ACID ETHYL ESTER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; LIVER TUMOR; LIVER WEIGHT; LYMPH NODE; LYMPHANGIOGENESIS; MICROVASCULATURE; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PROTEIN EXPRESSION; SCID MOUSE; STOMACH CANCER; THERAPY EFFECT; TUMOR GROWTH; TUMOR VOLUME;

EID: 84861695139     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X1201000103     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108. (Pubitemid 40372904)
2. Tajima Y, Yamazaki K, Makino R, et al. Gastric and intestinal phenotypic marker expression in early differentiated-type tumors of the stomach: clinicopathologic significance and genetic background. Clin Cancer Res 2006; 12:6469-79. (Pubitemid 44799720)
3. Choi J, Lee MK, Oh KH, et al. Interaction effect between the receptor for advanced glycation end products (RAGE) and high-mobility group box-1 (HMGB-1) for the migration of a squamous cell carcinoma cell line. Tumori 2011; 97:196-202.
4. Tang D, Kang R, Zeh HJ 3rd, Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta 2010; 1799:131-40.
5. Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, Stroncek D, Lim JB. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 2009; 7:38.
6. Huttunen HJ, Rauvala H. Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J Intern Med 2004; 255:351-66. (Pubitemid 38315276)
7. Kuniyasu H, Oue N, Wakikawa A, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002; 196:163-70. (Pubitemid 34110897)
8. Jing RR, Cui M, Sun BL, et al. Tissue-specific expression profiling of receptor for advanced glycation end products and its soluble forms in esophageal and lung cancer. Gent Test Mol Biomarkers 2010; 14:355-61.
9. Sasahira T, Akama Y, Fujii K, et al. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Archiv 2005; 446:411-15. (Pubitemid 40674848)
10. Kostova N, Zlateva S, Ugrinova I, et al. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 2010; 337:251-58.
11. Ishiguro H, Nakaigawa N, Miyoshi Y, et al. RAGE and its ligand amphoterin are over expressed and associated with prostate cancer development. Prostate 2005; 64:92-100. (Pubitemid 40734743)
12. Lee BL, Lee HS, Jung J, Cho SJ, Chung HY, Kim WH, Jin YW, Kim CS, Nam SY. Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer. Clin Cancer Res 2005; 11:2518-25. (Pubitemid 40569448)
13. Mino K, Ozaki M, Nakanishi K, et al. Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion. Cancer Sci 2011; 102:1052-8.
14. Davé SH, Tilstra JS, Matsuoka K, et al. Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biolm 2009; 86:633-43.
15. Chung KY, Park JJ, Kim YS. The role of high-mobility group box-1 in renal ischemia and reperfusion injury and the effect of ethyl pyruvate. Transplant Proc 2008; 40:2136-8.
16. Liang X, Chavez AR, Schapiro NE, et al. Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukoc Biol 2009; 86:599-607.
17. Lim SC, Choi JE, Kim CH, et al. Ethyl pyruvate induces necrosis-to-apoptosis switch and inhibits high mobility group box protein 1 release in A549 lung adenocarcinoma cells. Int J Mol Med 2007; 20:187-92.
18. Gnanasekar M, Thiragnanam S, Ramaswamy K. Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol 2009; 34:425-31.
19. Arumugam T, Ramachandran V, Logsdon CD. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 2006; 98:1806-18. (Pubitemid 46017932)
20. Turovskaya, Foell D, Sinha P, et al. RAGE carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008; 29:2035-43.
21. Spiller SE, Logsdon NJ, Deckard LA, Sontheimer H. Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo. BMC Cancer 2011; 11:136.
22. Tang D, Kang R, Zeh HJ 3rd, Lotze MT. High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal 2011; 14:1315-35.
23. Kösem M, Tuncer I, Kotan C, Ibiloǧlu I, Oztürk M, Türkdogan MK. Significance of VEGF and microvascular density in gastric carcinoma. Hepatogastroenterology 2009; 56:1236-40.
24. Zhu B, Lu L, Cai W, Yang X, Li C, Yang Z, Zhan W, Ma JX, Gao G. Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis. Mol Cancer Ther 2007; 6:3297-306.
25. Ueda J, Kajita M, Suenaga N, Fujii K, Seiki M. Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene 2003; 22:8716-22. (Pubitemid 38010495)
26. Temma T, Sano K, Kuge Y, Kamihashi J, Takai N, Ogawa Y, Saji H. Development of a radiolabeled probe for detecting membrane type-1 matrix metalloproteinase on malignant tumors. Biol Pharm Bull 2009; 32:1272-7.
27. Sasahira T, Kirita T, Bhawal UK, Ikeda M, Nagasawa A, Yamamoto K, Kuniyasu H. The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch 2007; 450:287-95. (Pubitemid 46376559)
28. Dutta S, Wang FQ, Wu HS, Mukherjee TJ, Fishman DA. The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC). Gynecol Oncol 2011; 123:129-37.
29. Qiu J, Xu J, Zheng Y, Wei Y, Zhu X, Lo EH, Moskowitz MA, Sims JR. HMGB1 promotes MMP-9 upregulation through TLR4 after cerebral ischemia Stroke 2010; 41:2077-82.
30. Bennett-Guerrero E, Swaminathan M, Grigore AM, et al. A phase II multicenter double-blind placebocontrolled study of ethyl pyruvate in high-risk patients undergoing cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2009; 23:324-29.